<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>170158_050</messagenumb>
		<messagesenderidentifier>NOVOPROD</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151548</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>US-NOVOPROD-369098</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>2</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20130116</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130116</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>US-NOVOPROD-369098</companynumb>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Faramarz</reportergivename>
			<reporterfamilyname>Ismail-Beigi</reporterfamilyname>
			<reporterorganization>Va Med Center</reporterorganization>
			<reporterstreet>10701 East Blvd 1B-129</reporterstreet>
			<reportercity>Cleveland</reportercity>
			<reporterstate>Ohio</reporterstate>
			<reporterpostcode>44106</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification>1</qualification>
			<studyname>Trial title:Liraglutide Effect and Action in Diabetes:Evaluation of cardiovascular outcome Results
</studyname>
			<sponsorstudynumb>EX2211-3748</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVOPROD</senderorganization>
			<senderdepartment>Product Safety and Clinical Quality Assurance</senderdepartment>
			<sendergivename>Novo</sendergivename>
			<sendermiddlename>Nordisk</sendermiddlename>
			<senderfamilyname>Inc.</senderfamilyname>
			<senderstreetaddress>100 College Road West</senderstreetaddress>
			<sendercity>Princeton</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>08540</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>6099875831</sendertel>
			<sendertelcountrycode>1</sendertelcountrycode>
			<senderfax>6099878480</senderfax>
			<senderfaxcountrycode>1</senderfaxcountrycode>
			<senderemailaddress>NNPI_AE_REPORTING@NOVONORDISK.COM</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDAEDI.CDER</receiverdepartment>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3018276504</receivertel>
			<receivertelcountrycode>1</receivertelcountrycode>
			<receiveremailaddress>WTaylor@OC.FDA.GOV</receiveremailaddress>
		</receiver>
		<patient>
			<patientinvestigationnumb>PRIVACY</patientinvestigationnumb>
			<patientonsetage>66</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientagegroup>6</patientagegroup>
			<patientweight>76.417</patientweight>
			<patientheight>166</patientheight>
			<patientsex>1</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Type 2 diabetes mellitus</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>1988</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Dyslipidaemia</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>2004</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Gastrooesophageal reflux disease</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>2008</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Retinopathy</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20040920</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Neuropathy peripheral</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>2001</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Renal failure chronic</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>2004</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Myocardial infarction</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypertension</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Left ventricular hypertrophy</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Pancreatitis</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>2000</patientmedicalstartdate>
				<patientmedicalcontinue>2</patientmedicalcontinue>
				<patientmedicalenddateformat>602</patientmedicalenddateformat>
				<patientmedicalenddate>2000</patientmedicalenddate>
				<patientmedicalcomment>Type? Acute</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Tobacco user</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Branch retinal vein occlusion</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Venous tributary (branch) occlusion of retina</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Retinal vein occlusion</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120904</reactionstartdate>
				<reactionfirsttime>259</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>136</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Liraglutide FlexPen</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>22-341</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Novo Nordisk A/S</drugauthorizationholder>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>0.0 mg, qd</drugdosagetext>
				<drugdosageform>Solution for injection</drugdosageform>
				<drugadministrationroute>058</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20111220</drugstartdate>
				<drugstartperiod>259</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>136</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20120421</drugenddate>
				<drugtreatmentduration>123</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>6</actiondrug>
				<activesubstance>
					<activesubstancename>liraglutide</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Retinal vein occlusion</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Unlikely</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Retinal vein occlusion</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Probable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Trial ID: EX2211-3748

Trial title: A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events. 
LEADER
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Phase: 3b

Investigational drugs: Liraglutide vs. Placebo

Patient ID: 912043 

Patient's height: 166 centimetres

This clinical trial case from the Unites States was reported as "branch retinal vein occlusion" and concerns a 66-year-old male patient. The patient was treated with trial drug Liraglutide vs. Placebo from 20-DEC-2011 to 21-APR-2012 for type 2 diabetes mellitus.

Medical history includes type 2 diabetes mellitus since 1988, dyslipidaemia, gastroesophageal reflux disease, nonproliferative retinopathy since 2004, neuropathy peripheral, chronic renal failure, myocardial infarction, hypertension, left ventricular hypertrophy and pancreatitis. The patient is a former smoker.

On 04-SEP-2012 the patient went to the general optometry for a comprehensive exam. Exam findings showed new branch retinal vein occlusion in the right eye. The patient had a follow up exam and the doctor felt that the retinal vein occlusion was mostly a systemic manifestation of hypertension (HTN), HLD and diabetes mellitus (DM). According to the doctor, vein occlusion when it comes to the retinal circulation is more common due to anatomic reasons and also considered to represent a frequent end-result of HTN. No concomitant medications associated.

Outcome of the event has not been reported.

Action taken to trial drug is reported as not applicable.

Investigator's causality:
Liraglutide vs. Placebo: probable

Sponsor's causality:
Liraglutide vs. Placebo: unlikely

On 23-JAN-2013 trial drug was un-blinded according to regulatory requirements. Information on actual treatment can be obtained from Global Safety for regulatory purposes.

On 25-JAN-2013 a correction was performed within regulatory timelines, Investigator's causality assesment in the narrtive was changed from possible to probable

Comment: company comment:
Blockage of smaller veins (branch veins) in the retina often occurs when retinal arteries that have been thickened or hardened by atherosclerosis and which cross over a retinal vein, can compress the vein and lead to changes in the flow and to thrombus formation. Hypertensive, atherosclerotic, inflammatory, or thrombophilic conditions may lead to retinal endothelial vascular damage. (1) This patient has multiple risk factors for atherosclerosis (hypertension, dyslipidaemia, myocardial infarction and type 2 diabetes). The diagnosis was made at an examination over four months after discontinuation of trial product, making date of onset of the event unclear. However, since GLP-1 analogues such as liraglutide have shown a neutral or favourable effect on many of these risk factors including hyperglycaemia, insulin resistance, dyslipidaemia, and hypertension, they may be expected to have a neutral or favourable effect on vascular events.

1. Wu L. Branch Retinal Vein Occlusion. http://emedicine.medscape.com/article/1223498-overview. 20-AUG-2012.</narrativeincludeclinical>
				<reportercomment>Investigator's alternative aetiology: Unknown</reportercomment>
				<sendercomment>Blockage of smaller veins (branch veins) in the retina often occurs when retinal arteries that have been thickened or hardened by atherosclerosis and which cross over a retinal vein, can compress the vein and lead to changes in the flow and to thrombus formation. Hypertensive, atherosclerotic, inflammatory, or thrombophilic conditions may lead to retinal endothelial vascular damage. (1) This patient has multiple risk factors for atherosclerosis (hypertension, dyslipidaemia, myocardial infarction and type 2 diabetes). The diagnosis was made at an examination over four months after discontinuation of trial product, making date of onset of the event unclear. However, since GLP-1 analogues such as liraglutide have shown a neutral or favourable effect on many of these risk factors including hyperglycaemia, insulin resistance, dyslipidaemia, and hypertension, they may be expected to have a neutral or favourable effect on vascular events.

1. Wu L. Branch Retinal Vein Occlusion. http://emedicine.medscape.com/article/1223498-overview. 20-AUG-2012.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
